Skip to main navigation Skip to search Skip to main content

A Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate with Trastuzumab as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Positive Breast Cancer

Project: Research

Project Details

StatusFinished
Effective start/end date07/12/11 → 02/8/14

Funding

  • Eisai Incorporated: $4,375.00